Nykode Therapeutics AS Company Description
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies.
The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer.
The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron.
Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
| Country | Norway |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Michael Engsig |
Contact Details
Address: Oslo Research Park Oslo, 0349 Norway | |
| Phone | 47 22 95 81 93 |
| Website | nykode.com |
Stock Details
| Ticker Symbol | VACBF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Thyring Engsig | Chief Executive Officer |
| Dr. Agnete B. Fredriksen Ph.D. | Co-Founder and Chief Scientific Officer |
| Harald Gurvin | Chief Financial Officer |
| Ulrich Blaschke | Chief Technology Officer |
| Louise Stubbe | Chief Legal Officer |